Defeat Rare Disease in Asia and Pacific (APAC) DRDA - Haemophilia
← catalyst calendarSponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
—
Status
Enrolling by invitation
Study type
Observational
Enrollment
244estimated
Sites
4
Countries
India, Malaysia, South Korea +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-31 | actual | When the study began enrolling |
| Primary completion | 2025-12-19 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-19 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Haemophilia
Intervention
- Other: No treatment given
Primary outcomes
what the primary-completion date above is the date OFEstimated prevalence of haemophilia
measured From start of data collection to end of data collection (approximately 5 months)
Estimated incidence of haemophilia
measured From start of data collection to end of data collection (approximately 5 months)
Estimated proportion of patients with haemophilia (PWH) who develop inhibitors (%)
measured From start of data collection to end of data collection (approximately 5 months)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed